KGA-2727
KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat) . KGA-2727 has antidiabetic efficacy[1].
Product Specifications
CAS Number
666842-36-0
UNSPSC
12352005
Hazard Statement
H302, H319
Target
SGLT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/kga-2727.html
Purity
98.84
Solubility
DMSO : 200 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic) |H2O : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(N)CCNCCCOC1=CC=C(CC2=C(C(C)C)NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)C(C)=C1
Molecular Formula
C26H40N4O8
Molecular Weight
536.62
Precautions
H302, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
SGLT1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
(R)-2-Cyclohexyl-2-hydroxyphenylacetic Acid
CRN (Corin, ATC2, CRN, Lrp4, TMPRSS10, Atrial Natriuretic Peptide-Converting Enzyme, Serine Protease, Heart-specific serine proteinase ATC2, Pro-ANP-converting enzyme)